PRMT8

Across TCGA pan-cancer cohorts, PRMT8 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRMT8 data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PRMT8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRMT8 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, LUAD, and PAAD are the cancer types where PRMT8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.128	0.783	.001	30	view →
LUAD	OS	Median	All	0.270	0.796	<.001	24	view →
PAAD	DFS	Median	All	0.100	0.484	.003	12	view →
ESCA	OS	Median	II,III,IV	0.226	0.686	.013	12	view →
UCEC	DFS	Median	All	0.974	0.827	.016	8	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRMT8–LIHC (OS)

Open the LIHC breakdown →